Drug intelligence / Profile preview

Seloxavir marboxil

Development stage: Phase 3
Lead developer: Zenshine Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Seloxavir marboxil, also known as ZX-7101A, is an antiviral drug developed by Nanjing Zenshine Pharmaceuticals. It acts as a cap-dependent endonuclease (CEN) inhibitor, targeting the polymerase acidic protein (PA) of the influenza virus. This mechanism prevents viral replication by inhibiting the "cap snatching" process essential for viral gene transcription. The drug is being developed for the treatment of uncomplicated influenza, demonstrating broad-spectrum antiviral activity against both influenza A and B viruses.

Brand names: Sebaloxavir Marboxil
Other names: 玛赛洛沙韦

Targets

CEN (Influenza A virus (2009 H1N1) polymerase acidic protein (PA) endonuclease)

Beyond the preview

Go deeper on Seloxavir marboxil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Seloxavir marboxil.

Explore the full profile